Case Reports in Immunology
Volume 2015 (2015), Article ID 524507, 4 pages
http://dx.doi.org/10.1155/2015/524507
Case Report
1Department of Hematology, Ankara University, Cebeci, 06590 Ankara, Turkey
2Department of Pulmonary Medicine, Immunology and Allergy Clinic, Ankara University, Cebeci, 06590 Ankara, Turkey
2Department of Pulmonary Medicine, Immunology and Allergy Clinic, Ankara University, Cebeci, 06590 Ankara, Turkey
Received 8 November 2014; Revised 1 January 2015; Accepted 1 January 2015
Academic Editor: Ahmad M. Mansour
Copyright © 2015 Pinar Ataca et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid drug desensitization method in patients who are allergic to rituximab. We report a low grade B cell non-Hodgkin lymphoma patient with rituximab hypersensitivity successfully treated with rapid drug desensitization. In experienced centers, drug desensitization is a novel modality to break through in case of hypersensitivity that should be considered.
No comments:
Post a Comment